Direct-to-consumer telehealth platform delivering treatments for weight loss, men's health, dermatology, and fertility.
Healthcare📍 New York, NYFounded 2017
Current Valuation
$7.0B
as of 2025
UNICORN
IPO Outlookrumored
Is Ro going public in 2026?
An IPO is rumored for 2026, with nothing filed. Ro remains private and the date is not the company's.
What is Ro's valuation in 2026?
Ro is valued at $7.0B as of 2025, set by its Series D ($150M, Feb 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Ro filed an S-1?
No public S-1 is on file for Ro as of 08/23/2026; the IPO is rumored.
Who are Ro's investors?
Ro's investors include General Catalyst, FirstMark Capital, ShawSpring Partners, Tiger Global, TQ Ventures, BoxGroup.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Ro is a direct-to-consumer telehealth platform that diagnoses patients, prescribes treatments, and delivers medication, with a particularly strong franchise in men's health (Roman), weight loss (compounded GLP-1s and Plenity), and fertility (Modern Fertility). Sacra estimates 2024 revenue at $598M (+66% YoY), and the company has held a $7B valuation since its 2022 Series D — well off its 2021 peak — with renewed IPO chatter as GLP-1 demand explodes.
Company Profile
CEO
Zachariah Reitano
Founded
2017
HQ
New York, NY
Employees
~1000
Total Raised
$1.0B
Est. Revenue
$598M (2024)
Growth
+66% YoY
Last Round
Series D — $150M (Feb 2022) · Lead: General Catalyst
IPO Status
rumored
Fundraising Status
Series D · $150M · 4y 6mo ago
rumoredTotal raised $1.0B
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$150M
Feb 2022
General Catalyst
—
Talent Signal
Hiring trend
▼ Hiring downtrend
4% of roles posted in last 30d
Open roles
51
via lever
Product-build share
69%
engineering, research, product, design
Trajectory
tightening
heavy product build — 69% of open roles are product-building functions (engineering/research/product) — 18 of 51 open roles are medical.
Open roles trending down; no tracked executive churn.
Counted from Ro's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Zachariah ReitanoSaman RahmanianRob Schutz
Investors
General Catalyst · FirstMark Capital · ShawSpring Partners · Tiger Global · TQ Ventures · BoxGroup
Products
Roman (men's health & ED)
Ro Body (GLP-1 weight loss)
Plenity
Modern Fertility
Ro Pharmacy
Workpath at-home diagnostics
Competitors
Hims & Hers · Noom · Teladoc · Lemonaid Health · Form Health
telehealthGLP-1weight-lossDTCpharmacy
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025. Refreshed quarterly.